Clinical and pharmacokinetic study of cefotetan in biliary tract infections: preliminary report.

Abstract

Twelve hospitalised patients, affected by biliary tract infections, were treated with cefotetan at dosages ranging between 4 and 6 g daily i.v. In only 11 patients was the aetiological agent identified. Eleven patients (91.67%) completely recovered from their infections and the pathogens were eradicated; the treatment failed in only 1 patient (8.33%). Furthermore, determinations were made of cefotetan concentrations in serum, gallbladder bile, gallbladder wall and gallstones of 14 patients undergoing cholecystectomy: in 7 patients after only 1 injection i.v. of 2 g and in 7 patients after 7 injections i.v. of 2 g at intervals of 12 h. The levels recorded were several times higher than the minimum inhibitory concentrations against bacteria that are most often responsible for biliary infections. Cefotetan is a promising and effective antimicrobial agent in the therapy of biliary tract infections.

• Authors: P Cristiano, R Lobello, M R Iovene, G De Ascentis, P Altucci, F Paradisi, L Manguso
• Journal: Chemioterapia : international journal of the Mediterranean Society of Chemotherapy (Chemioterapia) Vol. 7 Issue 4 Pg. 233-6 (Aug 1988) ISSN: 0392-906X [Print] Italy
• PMID: 3180302 (Publication Type: Journal Article)

Chemical References

• Cefotetan

Topics

• Adult
• Aged
• Bacterial Infections (drug therapy)
• Biliary Tract Diseases (drug therapy)
• Cefotetan (pharmacokinetics, therapeutic use)
• Cholecystectomy
• Female
• Humans
• Injections, Intravenous
• Male
• Middle Aged